Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy

Odelya E. Pagovich, Bo Wang, Maria J. Chiuchiolo, Stephen M. Kaminsky, Dolan Sondhi, Clarisse L. Jose, Christina C. Price, Sarah F. Brooks, Jason G. Mezey, Ronald Crystal

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background Peanuts are the most common food to provoke fatal or near-fatal anaphylactic reactions. Treatment with an anti-hIgE mAb is efficacious but requires frequent parenteral administration. Objective Based on the knowledge that peanut allergy is mediated by peanut-specific IgE, we hypothesized that a single administration of an adeno-associated virus (AAV) gene transfer vector encoding for anti-hIgE would protect against repeated peanut exposure in the host with peanut allergy. Methods We developed a novel humanized murine model of peanut allergy that recapitulates the human anaphylactic response to peanuts in NOD-scid IL2Rgammanull mice transferred with blood mononuclear cells from donors with peanut allergy and then sensitized with peanut extract. As therapy, we constructed an adeno-associated rh.10 serotype vector coding for a full-length, high-affinity, anti-hIgE antibody derived from the Fab fragment of the anti-hIgE mAb omalizumab (AAVrh.10anti-hIgE). In the reconstituted mice peanut-specific IgE was induced by peanut sensitization and hypersensitivity, and reactions were provoked by feeding peanuts to mice with symptoms similar to those of human subjects with peanut allergy. Results A single administration of AAVrh.10anti-hIgE vector expressed persistent levels of anti-hIgE. The anti-hIgE vector, administered either before sensitization or after peanut sensitization and manifestation of the peanut-induced phenotype, blocked IgE-mediated alterations in peanut-induced histamine release, anaphylaxis scores, locomotor activity, and free IgE levels and protected animals from death caused by anaphylaxis. Conclusion If this degree of persistent efficacy translates to human subjects, AAVrh.10anti-hIgE could be an effective 1-time preventative therapy for peanut allergy and possibly other severe, IgE-mediated allergies.

Original languageEnglish
Pages (from-to)1652-1662.e7
JournalJournal of Allergy and Clinical Immunology
Volume138
Issue number6
DOIs
Publication statusPublished - 1 Dec 2016
Externally publishedYes

Fingerprint

Peanut Hypersensitivity
Anaphylaxis
Genetic Therapy
Immunoglobulin E
Arachis
Dependovirus
Immunoglobulin Fab Fragments
Histamine Release
Locomotion
Anti-Idiotypic Antibodies
Blood Cells
Hypersensitivity
Therapeutics

Keywords

  • food allergy
  • gene therapy
  • IgE
  • mouse model
  • omalizumab
  • Peanut allergy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy. / Pagovich, Odelya E.; Wang, Bo; Chiuchiolo, Maria J.; Kaminsky, Stephen M.; Sondhi, Dolan; Jose, Clarisse L.; Price, Christina C.; Brooks, Sarah F.; Mezey, Jason G.; Crystal, Ronald.

In: Journal of Allergy and Clinical Immunology, Vol. 138, No. 6, 01.12.2016, p. 1652-1662.e7.

Research output: Contribution to journalArticle

Pagovich, OE, Wang, B, Chiuchiolo, MJ, Kaminsky, SM, Sondhi, D, Jose, CL, Price, CC, Brooks, SF, Mezey, JG & Crystal, R 2016, 'Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy', Journal of Allergy and Clinical Immunology, vol. 138, no. 6, pp. 1652-1662.e7. https://doi.org/10.1016/j.jaci.2016.03.053
Pagovich, Odelya E. ; Wang, Bo ; Chiuchiolo, Maria J. ; Kaminsky, Stephen M. ; Sondhi, Dolan ; Jose, Clarisse L. ; Price, Christina C. ; Brooks, Sarah F. ; Mezey, Jason G. ; Crystal, Ronald. / Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy. In: Journal of Allergy and Clinical Immunology. 2016 ; Vol. 138, No. 6. pp. 1652-1662.e7.
@article{170f70be5ec540b59dd1be3cf9d526b9,
title = "Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy",
abstract = "Background Peanuts are the most common food to provoke fatal or near-fatal anaphylactic reactions. Treatment with an anti-hIgE mAb is efficacious but requires frequent parenteral administration. Objective Based on the knowledge that peanut allergy is mediated by peanut-specific IgE, we hypothesized that a single administration of an adeno-associated virus (AAV) gene transfer vector encoding for anti-hIgE would protect against repeated peanut exposure in the host with peanut allergy. Methods We developed a novel humanized murine model of peanut allergy that recapitulates the human anaphylactic response to peanuts in NOD-scid IL2Rgammanull mice transferred with blood mononuclear cells from donors with peanut allergy and then sensitized with peanut extract. As therapy, we constructed an adeno-associated rh.10 serotype vector coding for a full-length, high-affinity, anti-hIgE antibody derived from the Fab fragment of the anti-hIgE mAb omalizumab (AAVrh.10anti-hIgE). In the reconstituted mice peanut-specific IgE was induced by peanut sensitization and hypersensitivity, and reactions were provoked by feeding peanuts to mice with symptoms similar to those of human subjects with peanut allergy. Results A single administration of AAVrh.10anti-hIgE vector expressed persistent levels of anti-hIgE. The anti-hIgE vector, administered either before sensitization or after peanut sensitization and manifestation of the peanut-induced phenotype, blocked IgE-mediated alterations in peanut-induced histamine release, anaphylaxis scores, locomotor activity, and free IgE levels and protected animals from death caused by anaphylaxis. Conclusion If this degree of persistent efficacy translates to human subjects, AAVrh.10anti-hIgE could be an effective 1-time preventative therapy for peanut allergy and possibly other severe, IgE-mediated allergies.",
keywords = "food allergy, gene therapy, IgE, mouse model, omalizumab, Peanut allergy",
author = "Pagovich, {Odelya E.} and Bo Wang and Chiuchiolo, {Maria J.} and Kaminsky, {Stephen M.} and Dolan Sondhi and Jose, {Clarisse L.} and Price, {Christina C.} and Brooks, {Sarah F.} and Mezey, {Jason G.} and Ronald Crystal",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.jaci.2016.03.053",
language = "English",
volume = "138",
pages = "1652--1662.e7",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy

AU - Pagovich, Odelya E.

AU - Wang, Bo

AU - Chiuchiolo, Maria J.

AU - Kaminsky, Stephen M.

AU - Sondhi, Dolan

AU - Jose, Clarisse L.

AU - Price, Christina C.

AU - Brooks, Sarah F.

AU - Mezey, Jason G.

AU - Crystal, Ronald

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background Peanuts are the most common food to provoke fatal or near-fatal anaphylactic reactions. Treatment with an anti-hIgE mAb is efficacious but requires frequent parenteral administration. Objective Based on the knowledge that peanut allergy is mediated by peanut-specific IgE, we hypothesized that a single administration of an adeno-associated virus (AAV) gene transfer vector encoding for anti-hIgE would protect against repeated peanut exposure in the host with peanut allergy. Methods We developed a novel humanized murine model of peanut allergy that recapitulates the human anaphylactic response to peanuts in NOD-scid IL2Rgammanull mice transferred with blood mononuclear cells from donors with peanut allergy and then sensitized with peanut extract. As therapy, we constructed an adeno-associated rh.10 serotype vector coding for a full-length, high-affinity, anti-hIgE antibody derived from the Fab fragment of the anti-hIgE mAb omalizumab (AAVrh.10anti-hIgE). In the reconstituted mice peanut-specific IgE was induced by peanut sensitization and hypersensitivity, and reactions were provoked by feeding peanuts to mice with symptoms similar to those of human subjects with peanut allergy. Results A single administration of AAVrh.10anti-hIgE vector expressed persistent levels of anti-hIgE. The anti-hIgE vector, administered either before sensitization or after peanut sensitization and manifestation of the peanut-induced phenotype, blocked IgE-mediated alterations in peanut-induced histamine release, anaphylaxis scores, locomotor activity, and free IgE levels and protected animals from death caused by anaphylaxis. Conclusion If this degree of persistent efficacy translates to human subjects, AAVrh.10anti-hIgE could be an effective 1-time preventative therapy for peanut allergy and possibly other severe, IgE-mediated allergies.

AB - Background Peanuts are the most common food to provoke fatal or near-fatal anaphylactic reactions. Treatment with an anti-hIgE mAb is efficacious but requires frequent parenteral administration. Objective Based on the knowledge that peanut allergy is mediated by peanut-specific IgE, we hypothesized that a single administration of an adeno-associated virus (AAV) gene transfer vector encoding for anti-hIgE would protect against repeated peanut exposure in the host with peanut allergy. Methods We developed a novel humanized murine model of peanut allergy that recapitulates the human anaphylactic response to peanuts in NOD-scid IL2Rgammanull mice transferred with blood mononuclear cells from donors with peanut allergy and then sensitized with peanut extract. As therapy, we constructed an adeno-associated rh.10 serotype vector coding for a full-length, high-affinity, anti-hIgE antibody derived from the Fab fragment of the anti-hIgE mAb omalizumab (AAVrh.10anti-hIgE). In the reconstituted mice peanut-specific IgE was induced by peanut sensitization and hypersensitivity, and reactions were provoked by feeding peanuts to mice with symptoms similar to those of human subjects with peanut allergy. Results A single administration of AAVrh.10anti-hIgE vector expressed persistent levels of anti-hIgE. The anti-hIgE vector, administered either before sensitization or after peanut sensitization and manifestation of the peanut-induced phenotype, blocked IgE-mediated alterations in peanut-induced histamine release, anaphylaxis scores, locomotor activity, and free IgE levels and protected animals from death caused by anaphylaxis. Conclusion If this degree of persistent efficacy translates to human subjects, AAVrh.10anti-hIgE could be an effective 1-time preventative therapy for peanut allergy and possibly other severe, IgE-mediated allergies.

KW - food allergy

KW - gene therapy

KW - IgE

KW - mouse model

KW - omalizumab

KW - Peanut allergy

UR - http://www.scopus.com/inward/record.url?scp=84977677057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977677057&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2016.03.053

DO - 10.1016/j.jaci.2016.03.053

M3 - Article

VL - 138

SP - 1652-1662.e7

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 6

ER -